Tissue Array
Log In | My Account | Cart (0 items) - $0.00
US Biomax, Inc.
 

BR963

Breast disease spectrum tissue array, including TNM and pathology grade, stage, TNM and IHC markers (ER, PR, Her-2 and p53), 48 cases/96 cores
Unstained: $225.00 Add to Cart
H&E (BR963s*): $225.00 Add to Cart

Microarray Panel:Breast disease spectrum tissue microarray, containing 1 case of normal tissue, 3 plasma cell mastitis, 3 adenosis, 3 fibroadenoma, 1 each of lobular carcinoma in situ and ductal carcinoma in situ, 34 invasive ductal carcinoma, 2 invasive lobular carcinoma, duplicate cores per case
Cores:96
Cases:48
Layout:12 cols × 8 rows
Core Diameter:1 mm
Thickness:5 µm
Applications:Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:1. Some slides are covered by a thin layer of paraffin to prevent oxidization and decay, thus are recommended be baked at 56-60°C up to 2 hours until the paraffin melt before doing regular IHC or ISH procedures.
2. For slides not coated with paraffin (those tissue cores can be easily seen on the glass), there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

  • Unstained: unstained paraffin tissue microarray slide.
  • Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
  • H & E: Hematoxylin and Eosin stained tissue microarray slide.

Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
123456789101112 
A Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
B Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
C Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
D Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
E Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
F Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
G Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
H Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Marked point
Legend: Bre - Breast

- Benign tumor, - Benign tumor, - Malignant tumor, - Malignant tumor, - Malignant tumor (stage 0), - Malignant tumor (stage I), - Malignant tumor (stage IIIa), - Malignant tumor (stage IIIb), - Malignant tumor (stage IIa), - Malignant tumor (stage IIb), - Malignant tumor (stage IV), - Normal tissue

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Grade Stage TNM ER PR P53 HER2 Type †
A1 1 F 49 Breast Normal breast tissue – – – ++,50% +++,50% – + Normal
A2 2 F 49 Breast Normal breast tissue – – – ++,40% +++,50% – + Normal
A3 3 F 28 Breast Plasma cell mastitis – – – +,5% +,50% +,30% – Benign
A4 4 F 28 Breast Plasma cell mastitis – – – +,5% +,50% +,30% – Benign
A5 5 F 32 Breast Plasma cell mastitis – – – – +,10% ++,30% – Benign
A6 6 F 32 Breast Plasma cell mastitis – – – – +,10% ++,30% – Benign
A7 7 F 35 Breast Plasma cell mastitis – – – +,5% +,30% ++,25% – Benign
A8 8 F 35 Breast Plasma cell mastitis – – – +,5% ++,40% ++,25% – Benign
A9 9 F 28 Breast Adenosis – – – ++,40% +++,30% +,50% + Benign
A10 10 F 28 Breast Adenosis – – – ++,40% +++,30% +,50% + Benign
A11 11 F 50 Breast Adenosis – – – – ++,50% – + Benign
A12 12 F 50 Breast Adenosis – – – – ++,50% – + Benign
B1 13 F 44 Breast Adenosis – – – ++,80% ++,80% +,50% + Benign
B2 14 F 44 Breast Adenosis – – – ++,80% ++,80% +,50% + Benign
B3 15 F 19 Breast Fibroadenoma – – – +,10% +++,80% +,70% ++ Benign
B4 16 F 19 Breast Fibroadenoma – – – +,10% +++,80% +,70% ++ Benign
B5 17 F 22 Breast Fibroadenoma – 0 TisN0M0 +++,60% +++,90% +,70% ++ Benign
B6 18 F 22 Breast Fibroadenoma – 0 TisN0M0 +++,60% +++,90% +,70% ++ Benign
B7 19 F 54 Breast Fibroadenoma – – – – +,10% +,50% – Benign
B8 20 F 54 Breast Fibroadenoma – – – – +,10% +,50% – Benign
B9 21 F 62 Breast Lobular carcinoma in situ – – – +,5% – +,50% +++ Malignant
B10 22 F 62 Breast Lobular carcinoma in situ (fibrous tissue) – – – N/A N/A N/A N/A Malignant
B11 23 F 45 Breast Ductal carcinoma in situ (Adenosis) – 0 TisN0M0 ++,50% +++,50% +,30% + Malignant
B12 24 F 45 Breast Ductal carcinoma in situ (ductal ectasia) – 0 TisN0M0 ++,50% +++,50% +,30% + Malignant
C1 25 F 52 Breast Invasive ductal carcinoma 1 IIa T2N0M0 – – ++,70% +++ Malignant
C2 26 F 52 Breast Invasive ductal carcinoma 1 IIa T2N0M0 – – ++,70% +++ Malignant
C3 27 F 58 Breast Invasive ductal carcinoma 1 IIa T2N0M0 ++,20% +,10% +,80% +++ Malignant
C4 28 F 58 Breast Invasive ductal carcinoma 1 IIIa T2N2M0 ++,20% +,10% +,80% +++ Malignant
C5 29 F 71 Breast Invasive ductal carcinoma 1–2 IIb T3N0M0 +++,80% +++,90% +,80% ++ Malignant
C6 30 F 71 Breast Invasive ductal carcinoma 1–2 IIIa T3N1M0 +++,80% +++,90% +,80% ++ Malignant
C7 31 F 59 Breast Invasive ductal carcinoma 1 IIa T2N0M0 ++,10% – +,40% ++ Malignant
C8 32 F 59 Breast Invasive ductal carcinoma 1 IIa T2N0M0 ++,10% – +,40% ++ Malignant
C9 33 F 43 Breast Invasive ductal carcinoma 1 IIa T2N0M0 ++,10% +,20% +,80% +++ Malignant
C10 34 F 43 Breast Invasive ductal carcinoma 1 IIIa T2N2M0 ++,10% +,20% +,80% +++ Malignant
C11 35 F 37 Breast Invasive ductal carcinoma 2 IIb T3N0M0 +,5% – +,20% ++ Malignant
C12 36 F 37 Breast Invasive ductal carcinoma 2 IIIa T3N1M0 +,5% – +,20% ++ Malignant
D1 37 F 49 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +,5% – ++,95% ++ Malignant
D2 38 F 49 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +,5% – ++,95% ++ Malignant
D3 39 F 32 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – +,80% – ++ Malignant
D4 40 F 32 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – +,80% – ++ Malignant
D5 41 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – +,10% +,80% +++ Malignant
D6 42 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – +,10% +,80% +++ Malignant
D7 43 F 53 Breast Invasive ductal carcinoma 1 IIa T2N0M0 ++,10% ++,20% +,60% ++ Malignant
D8 44 F 53 Breast Invasive ductal carcinoma 1 IIb T2N1M0 ++,10% ++,20% +,60% +++ Malignant
D9 45 F 62 Breast Invasive ductal carcinoma (chronic inflammation of breast tissue) – IIb T3N0M0 +++,50% ++,30% N/A N/A Malignant
D10 46 F 62 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +++,50% ++,30% +,50% +++ Malignant
D11 47 F 49 Breast Invasive ductal carcinoma (breast ductal tissue) – IIa T2N0M0 – – +,60% ++ Malignant
D12 48 F 49 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – +,60% ++ Malignant
E1 49 F 55 Breast Invasive ductal carcinoma 2 IIIb T4N1M0 ++,50% – +,60% ++ Malignant
E2 50 F 55 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 ++,50% – +,60% ++ Malignant
E3 51 F 52 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++,80% – – + Malignant
E4 52 F 52 Breast Invasive ductal carcinoma (sparse) 1 IIa T2N0M0 ++,80% – – + Malignant
E5 53 F 43 Breast Invasive ductal carcinoma 2 IIIb T4N2M0 +++,100% +++,100% +,100% – Malignant
E6 54 F 43 Breast Invasive ductal carcinoma 2 IIb T3N0M0 +++,100% +++,100% +,100% – Malignant
E7 55 F 42 Breast Invasive ductal carcinoma 2 IIIb T4N1M0 – – +,50% ++ Malignant
E8 56 F 42 Breast Invasive ductal carcinoma (fibrous tissue and blood vessel) – IIIa T2N2M0 – – N/A N/A Malignant
E9 57 F 57 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – +,95% +++ Malignant
E10 58 F 57 Breast Invasive ductal carcinoma (sparse) – IIa T2N0M0 – – +,95% +++ Malignant
E11 59 F 54 Breast Invasive ductal carcinoma 2 IIIb T4N2M0 – – +++,85% +++ Malignant
E12 60 F 54 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – – +++,85% +++ Malignant
F1 61 F 45 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +++,50% +++,50% ++,80% ++ Malignant
F2 62 F 45 Breast Invasive ductal carcinoma 2 IIb T3N0M0 +++,50% +++,50% ++,80% ++ Malignant
F3 63 F 37 Breast Invasive ductal carcinoma 3 IIb T3N1M0 – – ++,100% +++ Malignant
F4 64 F 37 Breast Invasive ductal carcinoma 3 IIb T2N1M0 – – ++,100% +++ Malignant
F5 65 F 69 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +++,90% – +,95% ++ Malignant
F6 66 F 69 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +++,90% – +,95% ++ Malignant
F7 67 F 56 Breast Invasive ductal carcinoma (Adenosis) – IIa T2N0M0 – – – ++ Malignant
F8 68 F 56 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – – – ++ Malignant
F9 69 F 47 Breast Invasive ductal carcinoma 3 IIb T3N1M0 – +,20% +++,80% +++ Malignant
F10 70 F 47 Breast Invasive ductal carcinoma 3 IIb T2N1M0 – +,15% +++,80% +++ Malignant
F11 71 F 48 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – ++,50% ++ Malignant
F12 72 F 48 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – ++,50% ++ Malignant
G1 73 F 58 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++,60% ++,10% +,95% + Malignant
G2 74 F 58 Breast Invasive ductal carcinoma 2 IIIb T4N1M0 ++,60% ++,10% +,95% + Malignant
G3 75 F 52 Breast Invasive ductal carcinoma (sparse) – IIa T2N0M0 +,10% +,20% N/A N/A Malignant
G4 76 F 52 Breast Invasive ductal carcinoma 3 IIb T2N1M0 +,10% +,20% +++,95% +++ Malignant
G5 77 F 58 Breast Invasive ductal carcinoma 2 IIb T3N1M0 +++,100% ++,10% +,95% +++ Malignant
G6 78 F 58 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +++,100% ++,10% +,95% +++ Malignant
G7 79 F 52 Breast Invasive ductal carcinoma 3 IIa T2N0M0 – – – ++ Malignant
G8 80 F 52 Breast Invasive ductal carcinoma 3 IIIb T4N1M0 – – – ++ Malignant
G9 81 F 45 Breast Invasive ductal carcinoma 3 IIa T2N0M0 – ++,30% +,20% ++ Malignant
G10 82 F 45 Breast Invasive ductal carcinoma 3 IIb T2N1M0 – ++,30% +,20% ++ Malignant
G11 83 F 71 Breast Invasive ductal carcinoma 3 IIb T3N1M0 ++,30% +,40% ++,10% + Malignant
G12 84 F 71 Breast Invasive ductal carcinoma 3 IIb T2N1M0 ++,40% +,35% ++,10% + Malignant
H1 85 F 44 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – +,10% ++ Malignant
H2 86 F 44 Breast Invasive ductal carcinoma 2 IV T3N1M1 – – ++,20% ++ Malignant
H3 87 F 65 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – +,5% ++ Malignant
H4 88 F 65 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – +,5% ++ Malignant
H5 89 F 41 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++,60% ++,60% +++,95% +++ Malignant
H6 90 F 41 Breast Invasive ductal carcinoma 2 I T1N0M0 ++,60% ++,60% +++,95% +++ Malignant
H7 91 F 75 Breast Invasive ductal carcinoma 3 IIb T2N1M0 +,20% – +,50% + Malignant
H8 92 F 75 Breast Invasive ductal carcinoma 3 IV T3N1M1 +,20% – +,50% + Malignant
H9 93 F 41 Breast Invasive lobular carcinoma – IIa T2N0M0 +,10% ++,50% +,10% – Malignant
H10 94 F 41 Breast Invasive lobular carcinoma – IIb T2N1M0 +,10% ++,50% +,10% – Malignant
H11 95 F 53 Breast Invasive lobular carcinoma – IIa T2N0M0 +++,90% ++,10% +,40% + Malignant
H12 96 F 53 Breast Invasive lobular carcinoma – I T1N0M0 +++,90% ++,10% +,40% + Malignant
– – M 58 Skin Malignant melanoma (tissue marker) – Malignant

† For precise diagnosis, refer to pathology description.

**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.

Staining Scoring: "-" - no staining; "+-" - borderline staining; "+" - weak staining; "++" - moderate staining; "+++" - strong staining; "%" - percentage of positive cells.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis

Find overlapping cases with this tissue array:
© 2003 - 2010 US Biomax Inc., custsrv@biomax.us, Tel: (800) 935-1357 | Privacy Policy

Authorize.Net Seal Starfield Seal